Kintor Pharmaceutical Limited (09939) said the company has obtained the approval for the Investigational New Drug (IND) application of Pyrilutamide (KX-826) gel formula for the indication of acne vulgaris from the National Medical Products Administration (NMPA) in China.
Pyrilutamide gel is a well-targeted topical AR antagonist, which competitively inhibits the combination of androgen with the AR in the skin tissue and is able to topically control the activation of the AR signal pathway caused by the excessive level of androgen without affecting the activity of the AR signal pathway in human body.
etnet榮獲HKEX Awards 2023 「最佳表現證券數據供應商」大獎► 了解詳情
